Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates

Archives of Ophthalmology

Volumn 129, Issue 8, 2011, Pages 1042-1052

  Nork, T Michael ^a   Dubielzig, Richard R ^a   Christian, Brian J ^b   Miller, Paul E ^a   Miller, Jacqueline M ^b   Cao, Jingtai ^c   Zimmer, Edward P ^c   Wiegand, Stanley J ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b 206 Carnegie Center   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EYE INFLAMMATION; FLUORESCENCE; HAPLORHINI; HISTOPATHOLOGY; LASER; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACACA FASCICULARIS; RECOMBINANT FUSION PROTEINS; RETINA;

EID: 80051573833     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.210     Document Type: Article

References (49)

1. Friedman DS, O'Colmain BJ, Muñoz B, et al Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572. (Pubitemid 38456293)
2. Congdon N, O'Colmain B, Klaver CC, et al Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485. (Pubitemid 38456282)
3. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol. 1986;104(5):694-701.
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109(9):1232-1241.
5. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109(9):1220-1231.
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol. 1993;111(9):1200-1209.
7. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol. 1994;112(4):500-509.
8. Macular Photocoagulation Study Group. Occult choroidal neovascularization: influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol. 1996;114(4):400-412.
9. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398. (Pubitemid 34920936)
10. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-346. (Pubitemid 34250056)
11. Ryan SJ. Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol. 1982;100(11):1804-1809. (Pubitemid 12006673)
12. Ohkuma H, Ryan SJ. Experimental subretinal neovascularization in the monkey: permeability of new vessels. Arch Ophthalmol. 1983;101(7):1102-1110. (Pubitemid 13067507)
13. Shen WY, Lee SY, Yeo I, et al. Predilection of the macular region to high incidence of choroidal neovascularization after intense laser photocoagulation in the monkey. Arch Ophthalmol. 2004;122(3):353-360. (Pubitemid 38314197)
14. Kaiser PK; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report No. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244(9):1132-1142.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816. (Pubitemid 40051904)
16. D'Amico DJ, Masonson HN, Patel M, et al VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113(6):992-1001, e6.
17. Rosenfeld PJ, Brown DM, Heier JS, et al MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. (Pubitemid 44511557)
18. Brown DM, Kaiser PK, Michels M, et al ANCHOR Study Group. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444. (Pubitemid 44511558)
19. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab vs verteporfin photodynamic therapy for neovascular agerelated macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65, e5.
20. Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: ranibizumab and bevacizumab controversy. Br J Ophthalmol. 2008;92(6):866-867.
21. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1-29. (Pubitemid 36207453)
22. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A. 1991;88(20):9267-9271. (Pubitemid 21915612)
23. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269(41):25646-25654.
24. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271(30):17629-17634. (Pubitemid 26250731)
25. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9(7):936-943. (Pubitemid 36889938)
26. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-583. (Pubitemid 32448325)
27. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64(1):162-169. (Pubitemid 34713242)
28. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(7):3186-3193. (Pubitemid 36759791)
29. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2(59):re1.
30. Murakami M, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 2006;108(6):1849-1856. (Pubitemid 44394993)
31. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195(2):241-248. (Pubitemid 36384298)
32. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7):1040-1050. (Pubitemid 38544126)
33. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45(8):2666-2673. (Pubitemid 38998863)
34. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci. 2010;51(11):6009-6017.
35. Dobi ET, Puliafito CA, Destro M. A new model of experimental choroidal neovascularization in the rat. Arch Ophthalmol. 1989;107(2):264-269. (Pubitemid 19055348)
36. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci. 1998;39(1):180-188. (Pubitemid 28040477)
37. Kiilgaard JF, Andersen MV, Wiencke AK, et al. A new animal model of choroidal neovascularization. Acta Ophthalmol Scand. 2005;83(6):697-704. (Pubitemid 41819292)
38. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113(6):810-818.
39. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103(3):427-438. (Pubitemid 26085897)
40. Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol. 1996;114(8):978-985. (Pubitemid 26271464)
41. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40(10):2322-2331. (Pubitemid 29418388)
42. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18(10):1573-1580.
43. Nguyen QD, Shah SM, Hafiz G, et al; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113(9):1522.e1-e1522.14.
44. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116(11):2141-2148, e1.
45. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;93(2):144-149.
46. Brown DM. One year results of a phase 2, randomized, controlled, dose- and interval-ranging study of intravitreal VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Paper presented at: 41st Annual Meeting of the Retina Society; September 28, 2008; Scottsdale, AZ.
47. Ho AC. Optical coherence tomography and fluorescein angiography outcomes through one year for a phase 2, randomized, controlled dose and interval ranging study of intravitreal VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Paper presented at: 41st Annual Meeting of the Retina Society; September 28, 2008; Scottsdale, AZ.
48. Vascular endothelial growth factor (VEGF) Trap-Eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW 1). http://clinicaltrials.gov/ct2/show/NCT00509795. Accessed June 3, 2011.
49. Vascular endothelial growth factor (VEGF) Trap-Eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW 2). http://clinicaltrials.gov/ct2/show/NCT00637377. Accessed June 3, 2011.